111 related articles for article (PubMed ID: 16278812)
1. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion.
Saunders PA; Hendrycks VR; Lidinsky WA; Woods ML
Eur J Immunol; 2005 Dec; 35(12):3561-9. PubMed ID: 16278812
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation.
Yang W; Li H; Chen PW; Alizadeh H; He Y; Hogan RN; Niederkorn JY
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):273-80. PubMed ID: 18791172
[TBL] [Abstract][Full Text] [Related]
3. Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions.
Tocheva AS; Peled M; Strazza M; Adam KR; Lerrer S; Nayak S; Azoulay-Alfaguter I; Foster CJR; Philips EA; Neel BG; Ueberheide B; Mor A
J Biol Chem; 2020 Dec; 295(52):18036-18050. PubMed ID: 33077516
[TBL] [Abstract][Full Text] [Related]
4. Adhering to adhesion: assessing integrin conformation to monitor T cells.
Gouttefangeas C; Schuhmacher J; Dimitrov S
Cancer Immunol Immunother; 2019 Nov; 68(11):1855-1863. PubMed ID: 31309255
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and its ligands in tolerance and immunity.
Keir ME; Butte MJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2008; 26():677-704. PubMed ID: 18173375
[TBL] [Abstract][Full Text] [Related]
6. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
Kinter AL; Godbout EJ; McNally JP; Sereti I; Roby GA; O'Shea MA; Fauci AS
J Immunol; 2008 Nov; 181(10):6738-46. PubMed ID: 18981091
[TBL] [Abstract][Full Text] [Related]
7. PD-L2 is expressed on activated human T cells and regulates their function.
Messal N; Serriari NE; Pastor S; Nunès JA; Olive D
Mol Immunol; 2011 Sep; 48(15-16):2214-9. PubMed ID: 21752471
[TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A
Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505
[TBL] [Abstract][Full Text] [Related]
9. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
Myklebust JH; Irish JM; Brody J; Czerwinski DK; Houot R; Kohrt HE; Timmerman J; Said J; Green MR; Delabie J; Kolstad A; Alizadeh AA; Levy R
Blood; 2013 Feb; 121(8):1367-76. PubMed ID: 23297127
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.
Patsoukis N; Sari D; Boussiotis VA
Cell Cycle; 2012 Dec; 11(23):4305-9. PubMed ID: 23032366
[TBL] [Abstract][Full Text] [Related]
11. Programmed death ligand 2 in cancer-induced immune suppression.
Rozali EN; Hato SV; Robinson BW; Lake RA; Lesterhuis WJ
Clin Dev Immunol; 2012; 2012():656340. PubMed ID: 22611421
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and PD-1 ligands: from discovery to clinical application.
Okazaki T; Honjo T
Int Immunol; 2007 Jul; 19(7):813-24. PubMed ID: 17606980
[TBL] [Abstract][Full Text] [Related]
13. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Li J; Jie HB; Lei Y; Gildener-Leapman N; Trivedi S; Green T; Kane LP; Ferris RL
Cancer Res; 2015 Feb; 75(3):508-518. PubMed ID: 25480946
[TBL] [Abstract][Full Text] [Related]
14. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
Baitsch L; Baumgaertner P; Devêvre E; Raghav SK; Legat A; Barba L; Wieckowski S; Bouzourene H; Deplancke B; Romero P; Rufer N; Speiser DE
J Clin Invest; 2011 Jun; 121(6):2350-60. PubMed ID: 21555851
[TBL] [Abstract][Full Text] [Related]
15. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells.
Good-Jacobson KL; Szumilas CG; Chen L; Sharpe AH; Tomayko MM; Shlomchik MJ
Nat Immunol; 2010 Jun; 11(6):535-42. PubMed ID: 20453843
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
Franke AJ; Skelton WP; Starr JS; Parekh H; Lee JJ; Overman MJ; Allegra C; George TJ
J Natl Cancer Inst; 2019 Nov; 111(11):1131-1141. PubMed ID: 31322663
[TBL] [Abstract][Full Text] [Related]
17. The blockade of immune checkpoints in cancer immunotherapy.
Pardoll DM
Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
Francisco LM; Salinas VH; Brown KE; Vanguri VK; Freeman GJ; Kuchroo VK; Sharpe AH
J Exp Med; 2009 Dec; 206(13):3015-29. PubMed ID: 20008522
[TBL] [Abstract][Full Text] [Related]
19. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
Agata Y; Kawasaki A; Nishimura H; Ishida Y; Tsubata T; Yagita H; Honjo T
Int Immunol; 1996 May; 8(5):765-72. PubMed ID: 8671665
[TBL] [Abstract][Full Text] [Related]
20. The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer.
Larson AC; Doty KR; Solheim JC
Cancer Med; 2024 May; 13(10):e7287. PubMed ID: 38770637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
